Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459998) titled 'SKB103 for Injection in Advanced Solid Tumors' on March 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Condition:
Advanced Solid Tumors
Intervention:
Drug: SKB103 for injection monotherapy
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: April 30, 2026
Target Sample Size: 277
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07459998
Disclaimer: Cur...